



Malmö 21 February 2022

PRESS RELEASE

Aptahem reports additional positive biological effect in a Corona virus-induced acute lung injury model treated with Aptahem-1

Aptahem can today announce that in addition to previously reported positive preliminary data, the Toronto team has, from further studies, found essential positive effects in a Corona virus challenge induced Acute Lung Injury model with Aptahem-1 treatment. Studies show that Aptahem-1 preliminary protects and recovers the lung tissue, significantly reduce the virus count and hemolysis, plus improves the clinical markers for the liver and kidneys. Previous studies show that Aptahem-1 supports and maintains systemic circulation, which is crucial to keeping the organism vital.

Research commissioned by Aptahem has, with these new results, added yet another level in understanding to the multifunctional properties of Aptahem-1 and its broadness to handle pathogen driven inflammatory situations. The results resonate very well with the findings from Aptahem's own studies and the collaboration with Örebro University.

The research is a continuance of the ongoing studies to map Aptahem-1's behaviour in a Corona viral lung injury model. Aptahem's third-party research partners have validated Aptahem's own LPS studies in their acute lung injury model. The new data further confirm Aptahem's results, hence essential evidence for Aptahem's claims on Aptahem-1 in severe inflammatory driven sicknesses like sepsis.

Aptahem has now commissioned additional research to continue to analyze other samples and plan the next steps for a preliminary extended collaboration that will bring further clarity on Aptahem-1 benefits and support Aptahem's continued growth and journey into becoming a clinical biotech company.

Dr Mikael Lindstam, CEO at Aptahem comments: "This preliminary positive effect on lung tissue is a milestone for us showing that we go from clarification to clarification regarding Aptahem-1's unique potential as a drug candidate. Our business case is strengthened by these characteristic effects and it helps us to optimize our soon to begin clinical journey towards needing patients."

Dr Luiza Jedlina, CSO at Aptahem, comments: "We are very happy to see the powers of Aptahem-1 in different severe inflammatory models and that the pathogen or other reasons that initiate or drive the inflammation seems not to matter. The latest results once again confirm our view on Aptahem-1's uniqueness, and we will continue to explore its capabilities further."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

Forward-looking statements

This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.

About Aptahem

Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The



Malmö 21 February 2022

PRESS RELEASE

company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.